jRCT2061260008
Not yet recruiting
Not Applicable
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Not provided0 sites4 target enrollmentStarted: TBD
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 4
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
Eligibility Criteria
- Ages
- 18age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.
Exclusion Criteria
- •Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable.
- •Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPsoriatic ArthritisjRCT20312600331,182
Not yet recruiting
Phase 1
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors2025-521702-18-00Novartis Pharma AG27
Not yet recruiting
Phase 1
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis2025-523265-15-00Candid Therapeutics Inc.9
Recruiting
Phase 3
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370
Not yet recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460Shanghai JMT-Bio Inc.1,800